Collegium Pharmaceutical (COLL) Invested Capital (2014 - 2026)

Collegium Pharmaceutical's Invested Capital history runs 13 years deep, the most recent figure standing at $345.0 million for Q1 2026.

• In Q1 2026, Invested Capital rose 15.39% year-over-year to $345.0 million; the TTM figure through Mar 2026 stood at $345.0 million (up 15.39% YoY), while the FY2025 annual figure was $330.7 million, up 12.69% from the prior year.
• Invested Capital was $345.0 million for Q1 2026 at Collegium Pharmaceutical, up from $330.7 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $797.2 million in Q3 2022 to a low of $227.2 million in Q2 2023.
• Historically, Invested Capital has averaged $359.5 million across 5 years, with a median of $339.8 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Invested Capital soared 111.97% in 2022, then plunged 54.56% in 2023.
• A 5-year view of Invested Capital shows it stood at $338.6 million in 2022, then increased by 11.86% to $378.8 million in 2023, then declined by 22.53% to $293.4 million in 2024, then rose by 12.69% to $330.7 million in 2025, then grew by 4.35% to $345.0 million in 2026.
• The last three Invested Capital figures came in at $345.0 million (Q1 2026), $330.7 million (Q4 2025), and $274.8 million (Q3 2025), per Business Quant data.